-+ 0.00%
-+ 0.00%
-+ 0.00%

Instinct Bio named CelSiege representative for IN01 cancer immunotherapy in Japan, China

PUBT·10/01/2026 10:10:20
Instinct Bio named CelSiege representative for IN01 cancer immunotherapy in Japan, China
  • Instinct Bio was appointed CelSiege Biosciences’ non-exclusive authorized representative for IN01 cancer immunotherapy in Japan, China.
  • Mandate covers introductions to potential partners, investors, pharma groups, medical institutions, research organizations, investment funds.
  • Scope includes facilitating early talks on licensing, co-development, clinical development, manufacturing, commercialization.
  • Letter of Authorisation was signed Sept. 18, 2026; any transaction requires separate negotiations, due diligence, definitive agreements.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Instinct Bio Technical Company Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-112508), on October 01, 2026, and is solely responsible for the information contained therein.